Key result
This editorial reviews recent cardiovascular studies, highlighting that ESC thrombotic risk criteria have modest predictive ability for MACE and that RAS blockers may be continued in non-severe COVID-19.
Design
Editorial
Authors
Loading...
This editorial summarizes recent studies on cardiovascular pharmacotherapy, including risk stratification post-PCI, NOACs in low-risk AF, NSAIDs and PE risk, subcutaneous furosemide, SGLT2 inhibitors and potassium levels, and RAS blockers in COVID-19.
Stefan Agewall (2023) conducted an editorial in Cardiovascular disease. Cardiovascular therapies and risk stratification was evaluated. This editorial reviews recent cardiovascular studies, highlighting that ESC thrombotic risk criteria have modest predictive ability for MACE and that RAS blockers may be continued in non-severe COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: